Context Therapeutics Inc. (CNTX) Files 1.5M Share IPO at $12-$14/sh

Context Therapeutics Inc. (NASDAQ: CNTX) has filed to IPO 1,500,000 shares at $12-$14 per share.

Context Therapeutics® is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. Profound advancements in oncology drug development have expanded the treatment options available to women with cancer, yet therapeutic resistance and relapse continue to limit the efficacy and duration of such treatments. Collectively, CNTX founders and management team have decades of experience identifying and characterizing the mechanisms that drive cancer initiation and subsequent relapse in women with cancer and have been associated with the development of products such as Kisqali (ribociclib), Arimidex (anastrozole) and Afinitor (everolimus) to treat such cancers.

ThinkEquity will serve as sole underwriter.

You May Also Be Interested In

• Aggreko files for proposed IPO
• Grace Therapeutics (GRCE) files for 4.76M share offering by selling stockholders
• Oppenheimer adds managing director, promotes municipal leader